| 1.25 -0.12 (-8.76%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.14  |
1-year : | 2.6 |
| Resists | First : | 1.84 |
Second : | 2.23 |
| Pivot price | 1.46  |
|||
| Supports | First : | 1.21 |
Second : | 1 |
| MAs | MA(5) : | 1.33 |
MA(20) : | 1.53 |
| MA(100) : | 1.26 |
MA(250) : | 1.34 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 11.4 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 2.23 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BNGO ] has closed above bottom band by 6.5%. Bollinger Bands are 90.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.39 |
| Low: | 1.23 - 1.24 | 1.24 - 1.25 |
| Close: | 1.24 - 1.25 | 1.25 - 1.26 |
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Wed, 09 Sep 2026
Bionano Genomics (BNGO) interim CEO adds 4,000 shares in IRA - Stock Titan
Fri, 21 Aug 2026
Bionano Genomics (NASDAQ: BNGO) interim CEO buys 4,000 shares - Stock Titan
Mon, 17 Aug 2026
Bionano Genomics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Mon, 17 Aug 2026
Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Mon, 10 Aug 2026
Earnings call transcript: Bionano Genomics tops Q2 revenue view, shares edge up - Investing.com
Mon, 10 Aug 2026
Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 12.9 (%) |
| Shares Short | 2,040 (K) |
| Shares Short P.Month | 1,220 (K) |
| EPS | -2.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | -106.6 % |
| Operating Margin | -88.4 % |
| Return on Assets (ttm) | -32.6 % |
| Return on Equity (ttm) | -83.6 % |
| Qtrly Rev. Growth | 21.3 % |
| Gross Profit (p.s.) | 1.21 |
| Sales Per Share | 2.56 |
| EBITDA (p.s.) | -1.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.46 |
| Price to Sales | 0.48 |
| Price to Cash Flow | -0.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|